Supplementary Appendix

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Supplementary Appendix"

Transcription

1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375: DOI: /NEJMoa

2 Supplement to: Wanner C, Inzucchi SE, Lachin J, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. Figure S1. Pre-specified subgroup analyses for incident or worsening nephropathy Figure S2. Incident or worsening nephropathy with empagliflozin 10 mg, empagliflozin 25 mg and placebo... 3 Figure S3. Incident or worsening nephropathy or cardiovascular death with empagliflozin and placebo... 4 Figure S4. Incident or worsening nephropathy with empagliflozin and placebo in patients with prevalent kidney disease defined as egfr (MDRD) <60 ml/min/1.73m 2 and/or macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline... 6 Figure S5. Composite of doubling of serum creatinine (accompanied by egfr [MDRD] 45 ml/min/1.73m 2 ), initiation of renal replacement therapy, or death due to renal disease in patients with macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline... 7 Figure S6. Post-hoc subgroup analyses of doubling of serum creatinine, initiation of renal replacement therapy, or death due to renal disease Figure S7. egfr according to CKD-EPI formula over 192 weeks in patients with egfr <60 ml/min/1.73m 2 and 60 ml/min/1.73m 2 at baseline Figure S8. Adverse events with empagliflozin compared with placebo Figure S9. Acute renal failure and acute kidney injury with empagliflozin and placebo Table S1. Baseline characteristics of patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Table S2. Cardiovascular medications introduced post-baseline in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Table S3. Composite microvascular outcome with empagliflozin compared with placebo Table S4. Incident or worsening nephropathy and incident or worsening nephropathy or cardiovascular death: pre-specified analysis and post-hoc sensitivity analysis Table S5. Incident or worsening nephropathy and incident or worsening nephropathy or cardiovascular death with empagliflozin compared with placebo in patients with prevalent kidney disease defined as egfr (MDRD) <60 ml/min/1.73m 2 and/or macroalbuminuria (urine albuminto-creatinine ratio >300 mg/g) at baseline Table S6. Adverse events in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Table S7. Complicated urinary tract infections by MedDRA preferred term in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Table S8. Changes in clinical laboratory parameters in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline

3 Figure S1. Pre-specified subgroup analyses for incident or worsening nephropathy. Cox regression analyses in patients treated with 1 dose of study drug. p-value is for test of homogeneity of treatment group difference among subgroups (test for treatment group by covariate interaction) with no adjustment for multiple testing. ACE, angiotensin-converting enzyme. ARB, angiotensin-receptor blocker. DBP, diastolic blood pressure. SBP, systolic blood pressure. 2

4 Figure S2. Incident or worsening nephropathy with empagliflozin 10 mg, empagliflozin 25 mg and placebo Kaplan-Meier estimates of time to first occurrence of incident or worsening nephropathy in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups in patients treated with 1 dose of study drug. Hazard ratio is based on Cox regression analysis. Pre-specified analyses. 3

5 Figure S3. Incident or worsening nephropathy or cardiovascular death with empagliflozin and placebo Kaplan-Meier estimates of time to first occurrence of incident or worsening nephropathy or cardiovascular death in the empagliflozin pooled and placebo groups (Panel A) and in the empagliflozin 10 mg, empagliflozin 25 mg and placebo groups (Panel B) in patients treated with 1 dose of study drug. Hazard ratios are based on Cox regression analyses. Pre-specified analyses. A Empagliflozin pooled and placebo groups 4

6 B Empagliflozin 10 mg, empagliflozin 25 mg and placebo groups 5

7 Figure S4. Incident or worsening nephropathy with empagliflozin and placebo in patients with prevalent kidney disease defined as egfr (MDRD) <60 ml/min/1.73m 2 and/or macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline Kaplan-Meier estimates of time to first occurrence of incident or worsening nephropathy in the empagliflozin and placebo groups in patients with prevalent kidney disease treated with 1 dose of study drug. Hazard ratio is based on Cox regression analysis. Post-hoc analyses. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. 6

8 Figure S5. Composite of doubling of serum creatinine (accompanied by egfr [MDRD] 45 ml/min/1.73m 2 ), initiation of renal replacement therapy, or death due to renal disease in patients with macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline Kaplan-Meier estimates in empagliflozin and placebo groups in patients with macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline treated with 1 dose of study drug. Hazard ratio is based on Cox regression analysis. Post-hoc analyses. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. 7

9 Figure S6. Post-hoc subgroup analyses of doubling of serum creatinine, initiation of renal replacement therapy, or death due to renal disease. Cox regression analyses in patients treated with 1 dose of study drug. p-value is for test of homogeneity of treatment group difference among subgroups (test for treatment group by covariate interaction) with no adjustment for multiple testing. 8

10 Figure S7. egfr according to CKD-EPI formula over 192 weeks in patients with egfr <60 ml/min/1.73m 2 and 60 ml/min/1.73m 2 at baseline. egfr according to CKD-EPI formula over 192 weeks in patients with egfr <60 ml/min/1.73m2 at baseline (Panel A) and 60 ml/min/1.73m2 at baseline (Panel B). egfr category at baseline is according to the MDRD formula. Post-hoc analysis. Mixed model repeated measures analysis, including baseline glycated hemoglobin as a linear covariate and region, baseline egfr (MDRD), baseline body mass index, the last week a patient could have had egfr measurements, treatment, visit, visit by treatment interaction, baseline glycated hemoglobin by visit interaction, baseline egfr by visit interaction, baseline egfr by treatment interaction and baseline egfr by visit by treatment interaction as fixed effects, in patients treated with 1 dose of study drug. egfr, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease. A Patients with egfr <60 ml/min/1.73m 2 at baseline 9

11 B Patients with egfr 60 ml/min/1.73m 2 at baseline 10

12 Figure S8. Adverse events with empagliflozin compared with placebo. Incidence rate ratios (based on rate per 100 patient-years) for empagliflozin compared with placebo based on post-hoc assessments. Data are from patients treated with 1 dose of study drug based on events that occurred during treatment or 7 days after the last intake of study drug. 11

13 * Plasma glucose 70 mg/dl and/or requiring assistance. Based on 79 MedDRA preferred terms. Pyelonephritis, urosepsis or serious adverse event consistent with urinary tract infection. Based on 88 MedDRA preferred terms. Based on 8 MedDRA preferred terms. ǁ Based on the narrow standardized MedDRA query acute renal failure. ** Based on 1 standardized MedDRA query. Based on 62 MedDRA preferred terms. Based on 2 MedDRA preferred terms. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. MedDRA, Medical Dictionary for Regulatory Activities. 12

14 Figure S9. Acute renal failure and acute kidney injury with empagliflozin and placebo. Kaplan-Meier estimates of time to first occurrence of acute renal failure based on the narrow standardized MedDRA query acute renal failure and time to first occurrence of acute kidney injury (MedDRA preferred term) in the empagliflozin and placebo groups in patients treated with 1 dose of study drug based on events that occurred during treatment or 7 days after the last intake of study drug. Post-hoc analyses. MedDRA, Medical Dictionary for Regulatory Activities. 13

15 Table S1. Baseline characteristics of patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Patients with egfr (MDRD) <60 ml/min/1.73m 2 at baseline Patients with egfr (MDRD) 60 ml/min/1.73m 2 at baseline Characteristic* Placebo (N=607) Empagliflozin (N=1212) Placebo (N=1726) Empagliflozin (N=3473) Age years 67.1± ± ± ±8.5 Male no. (%) 418 (68.9) 816 (67.3) 1262 (73.1) 2518 (72.5) Race no. (%) White 444 (73.1) 878 (72.4) 1234 (71.5) 2524 (72.7) Asian 132 (21.7) 265 (21.9) 379 (22.0) 741 (21.3) Black/African-American 27 (4.4) 56 (4.6) 93 (5.4) 181 (5.2) Other/Missing 4 (0.7) 13 (1.1) 20 (1.2) 27 (0.8) Ethnicity no. (%) Not Hispanic or Latino 507 (83.5) 1000 (82.5) 1405 (81.4) 2835 (81.6) Hispanic or Latino 99 (16.3) 211 (17.4) 319 (18.5) 634 (18.3) Missing 1 (0.2) 1 (0.1) 2 (0.1) 4 (0.1) Region no. (%) Europe 210 (34.6) 418 (34.5) 749 (43.4) 1508 (43.4) North America (plus Australia and 175 (28.8) 329 (27.1) 287 (16.6) 603 (17.4) New Zealand) Asia 113 (18.6) 232 (19.1) 337 (19.5) 665 (19.1) Latin America 79 (13.0) 174 (14.4) 281 (16.3) 545 (15.7) Africa 30 (4.9) 59 (4.9) 72 (4.2) 152 (4.4) Weight kg 87.1± ± ± ±18.7 Body mass index kg/m ± ± ± ±5.2 CV risk factor no. (%) 601 (99.0) 1203 (99.3) 1706 (98.8) 3452 (99.4) Coronary artery disease 482 (79.4) 938 (77.4) 1281 (74.2) 2606 (75.0) Multi-vessel coronary artery 331 (54.5) 610 (50.3) 769 (44.6) 1569 (45.2) disease History of myocardial infarction 264 (43.5) 559 (46.1) 819 (47.5) 1630 (46.9) Coronary artery bypass graft 196 (32.3) 380 (31.4) 367 (21.3) 795 (22.9) History of stroke 156 (25.7) 293 (24.2) 397 (23.0) 791 (22.8) Peripheral artery disease 130 (21.4) 314 (25.9) 349 (20.2) 667 (19.2) Single vessel coronary artery 54 (8.9) 108 (8.9) 184 (10.7) 390 (11.2) 14

16 disease Cardiac failure 89 (14.7) 174 (14.4) 155 (9.0) 288 (8.3) Glycated hemoglobin ǁ % 8.03± ± ± ±0.84 Time since diagnosis of type 2 diabetes no. (%) 1 years 9 (1.5) 23 (1.9) 43 (2.5) 105 (3.0) >1 to 5 years 55 (9.1) 121 (10.0) 316 (18.3) 591 (17.0) >5 to 10 years 121 (19.9) 274 (22.6) 450 (26.1) 901 (25.9) >10 years 422 (69.5) 794 (65.5) 917 (53.1) 1876 (54.0) Glucose-lowering therapy no. (%) Medication taken alone or in combination Metformin 369 (60.8) 711 (58.7) 1365 (79.1) 2746 (79.1) Sulfonylurea 234 (38.6) 480 (39.6) 758 (43.9) 1534 (44.2) Thiazolidinedione 27 (4.4) 62 (5.1) 74 (4.3) 136 (3.9) Insulin 357 (58.8) 699 (57.7) 778 (45.1) 1551 (44.7) Monotherapy 217 (35.7) 430 (35.5) 474 (27.5) 950 (27.4) Dual therapy 279 (46.0) 530 (43.7) 869 (50.3) 1727 (49.7) Anti-hypertensive therapy no. (%) 590 (97.2) 1186 (97.9) 1631 (94.5) 3259 (93.8) Angiotensin-converting enzyme 502 (82.7) 1031 (85.1) 1366 (79.1) 2766 (79.6) inhibitors/angiotensin receptor blockers Beta-blockers 415 (68.4) 829 (68.4) 1083 (62.7) 2226 (64.1) Diuretics 355 (58.5) 710 (58.6) 633 (36.7) 1336 (38.5) Calcium channel blockers 227 (37.4) 446 (36.8) 561 (32.5) 1082 (31.2) Mineralocorticoid receptor 48 (7.9) 119 (9.8) 88 (5.1) 186 (5.4) antagonists Renin inhibitors 5 (0.8) 12 (1.0) 14 (0.8) 15 (0.4) Other 70 (11.5) 144 (11.9) 121 (7.0) 239 (6.9) Lipid-lowering therapy no. (%) 496 (81.7) 1024 (84.5) 1368 (79.3) 2795 (80.5) Statins 461 (75.9) 966 (79.7) 1312 (76.0) 2663 (76.7) Fibrates 80 (13.2) 173 (14.3) 119 (6.9) 258 (7.4) Ezetimibe 31 (5.1) 43 (3.5) 50 (2.9) 146 (4.2) Niacin 15 (2.5) 22 (1.8) 20 (1.2) 69 (2.0) Other 72 (11.9) 127 (10.5) 103 (6.0) 238 (6.9) 15

17 Anti-coagulants no. (%) 552 (90.9) 1087 (89.7) 1538 (89.1) 3074 (88.5) Acetylsalicylic acid 495 (81.5) 981 (80.9) 1432 (83.0) 2894 (83.3) Clopidogrel 56 (9.2) 133 (11.0) 193 (11.2) 361 (10.4) Vitamin K antagonists 63 (10.4) 100 (8.3) 93 (5.4) 166 (4.8) Systolic blood pressure mmhg 136.4± ± ± ±16.6 Diastolic blood pressure mmhg 74.6± ± ± ±9.5 Total cholesterol mg/dl** 163.0± ± ± ±44.4 Low density lipoprotein cholesterol 85.0± ± ± ±36.0 mg/dl High density lipoprotein cholesterol 42.9± ± ± ±11.7 mg/dl** Triglycerides mg/dl** 180.4± ± ± ±136.4 Estimated glomerular filtration rate 48.6± ± ± ±17.1 (MDRD) ml/min/1.73m 2 Urine albumin-to-creatinine ratio no. (%) <30 mg/g 283 (46.6) 566 (46.7) 1099 (63.7) 2223 (64.0) 30 to 300 mg/g 205 (33.8) 411 (33.9) 470 (27.2) 926 (26.7) >300 mg/g 115 (18.9) 223 (18.4) 145 (8.4) 286 (8.2) Missing 4 (0.7) 12 (1.0) 12 (0.7) 38 (1.1) * Plus minus values are means ± SD. Body mass index is the weight in kilograms divided by the square of the height in meters. Information was not available for one patient in the placebo group with 60 ml/min/1.73m 2 at baseline. Information was not available for one patient in the placebo group and one patient in the empagliflozin 25 mg group with 60 ml/min/1.73m 2 at baseline. Based on the narrow standardized MedDRA query cardiac failure. ǁ Information was not available for one patient in the empagliflozin 10 mg group with 60 ml/min/1.73m 2 at baseline. ** Placebo n=598 and empagliflozin n=1202 for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1711 and empagliflozin n=3423 for patients with egfr 60 ml/min/1.73m 2 at baseline. Placebo n=598 and empagliflozin n=1201 for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1711 and empagliflozin n=3421 for patients with egfr 60 ml/min/1.73m 2 at baseline. Post-hoc assessment: p<0.05 for difference between empagliflozin and placebo based on Chi-square test for binary/categorical variables or t-test for continuous variables. MDRD, Modification of Diet in Renal Disease. MedDRA, Medical Dictionary for Regulatory Activities. 16

18 Table S2. Cardiovascular medications introduced post-baseline in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Patients with egfr <60 ml/min/1.73m 2 at baseline Placebo Empagliflozin Patients with egfr 60 ml/min/1.73m 2 at baseline Placebo Empagliflozin (N = 607) (N = 1212) (N = 1726) (N = 3473) Anti-hypertensive therapies no. (%) 359 (59.1) 624 (51.5) 831 (48.1) 1463 (42.1) Angiotensin-converting enzyme 202 (33.3) 359 (29.6) 500 (29.0) 864 (24.9) inhibitors/angiotensin receptor blockers Beta-blockers 136 (22.4) 256 (21.1) 345 (20.0) 602 (17.3) Diuretics 227 (37.4) 327 (27.0) 381 (22.1) 572 (16.5) Calcium channel blockers 137 (22.6) 231 (19.1) 344 (19.9) 441 (12.7) Mineralocorticoid receptor 54 (8.9) 64 (5.3) 82 (4.8) 113 (3.3) antagonists Renin inhibitors 2 (0.3) 4 (0.3) 4 (0.2) 5 (0.1) Other 62 (10.2) 106 (8.7) 103 (6.0) 168 (4.8) Lipid-lowering therapies no. (%) 207 (34.1) 354 (29.2) 512 (29.7) 1012 (29.1) Statins 169 (27.8) 289 (23.8) 432 (25.0) 856 (24.6) Fibrates 41 (6.8) 53 (4.4) 87 (5.0) 158 (4.5) Ezetimibe 17 (2.8) 25 (2.1) 32 (1.9) 69 (2.0) Niacin 5 (0.8) 7 (0.6) 10 (0.6) 16 (0.5) Other 24 (4.0) 35 (2.9) 47 (2.7) 74 (2.1) Anti-coagulants no. (%) 213 (35.1) 391 (32.3) 495 (28.7) 949 (27.3) Acetylsalicylic acid 127 (20.9) 238 (19.6) 327 (18.9) 602 (17.3) Clopidogrel 36 (5.9) 82 (6.8) 98 (5.7) 179 (5.2) Vitamin K antagonists 43 (7.1) 60 (5.0) 59 (3.4) 99 (2.9) Patients treated with 1 dose of study drug. Cardiovascular medications introduced post-baseline irrespective of study medication intake. MDRD, Modification of Diet in Renal Disease. 17

19 Table S3. Composite microvascular outcome with empagliflozin compared with placebo Placebo No. with event/ analyzed (%) Rate/1000 patient-yr No. with event/ analyzed (%) Empagliflozin Rate/1000 patient-yr Hazard ratio (95% CI) p-value Composite microvascular 424/2068 (20.5) /4132 (14.0) (0.54, 0.70) <0.001 outcome Initiation of laser 29/2333 (1.2) /4687 (0.9) (0.43, 1.12) therapy for retinopathy Vitreous hemorrhage 16/2333 (0.7) /4687 (0.6) (0.51, 1.71) Diabetes-related 2/2333 (0.1) 0.3 4/4687 (0.1) 0.3 blindness* Incident or worsening nephropathy 388/2061 (18.8) /4124 (12.7) (0.53, 0.70) <0.001 Prespecified Cox regression analyses in patients treated with 1 dose of study drug. *Hazard ratio and 95% CI were not analyzed as the total number of patients with events was <14. 18

20 Table S4. Incident or worsening nephropathy and incident or worsening nephropathy or cardiovascular death: pre-specified analysis and post-hoc sensitivity analysis Incident or worsening nephropathy Placebo Empagliflozin Hazard ratio No. with event/ Rate/1000 No. with event/ Rate/1000 (95% CI) analyzed (%) patient-yr analyzed (%) patient-yr p-value Pre-specified analysis* 388/2061 (18.8) /4124 (12.7) (0.53, 0.70) <0.001 Sensitivity analysis 388/2333 (16.6) /4687 (11.2) (0.53, 0.69) <0.001 Incident or worsening nephropathy or cardiovascular death Pre-specified analysis* 497/2102 (23.6) /4170 (16.2) (0.55, 0.69) <0.001 Sensitivity analysis 497/2333 (21.3) /4687 (14.4) (0.54, 0.69) <0.001 * Patients treated with 1 dose of study drug not considering patients with macroalbuminuria at baseline and/or patients without baseline and/or post-baseline serum creatinine measurements and/or patients without post-baseline urine albumin-to-creatinine ratio measurements (unless they experienced at least one of the other components of the composite renal outcome). All patients treated with 1 dose of study drug. 19

21 Table S5. Incident or worsening nephropathy and incident or worsening nephropathy or cardiovascular death with empagliflozin compared with placebo in patients with prevalent kidney disease defined as egfr (MDRD) <60 ml/min/1.73m 2 and/or macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g) at baseline Placebo No. with event/ analyzed (%) Rate/1000 patient-yr Empagliflozin No. with event/ Rate/1000 analyzed (%) patient-yr Hazard ratio (95% CI) p-value Incident or worsening 161/507 (31.8) /998 (20.7) (0.47, 0.71) <0.001 nephropathy Incident or worsening nephropathy or cardiovascular death 213/539 (39.5) /1039 (27.9) (0.53, 0.76) <0.001 Post-hoc Cox regression analyses in patients with prevalent kidney disease treated with 1 dose of study drug. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. 20

22 Table S6. Adverse events in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline. Event Patients with egfr (MDRD) <60 ml/min/1.73m 2 at baseline Placebo Pooled empagliflozin (N = 607) (N = 1212) No. (%) Rate per No. (%) Rate per with one or 100-patient with one or 100-patient more event years more event years Patients with egfr (MDRD) 60 ml/min/1.73m 2 at baseline Placebo Pooled empagliflozin (N = 1726) (N = 3473) No. (%) Rate per No. (%) Rate per with one or 100-patient with one or 100-patient more event years more event years Any adverse event 577 (95.1) (91.3) (90.5) (89.9) Rate ratio (95% CI) 0.70 ( ) 0.88 ( ) Severe adverse event 208 (34.3) (29.7) (22.2) (21.3) 9.1 Rate ratio (95% CI) 0.81 ( ) 0.92 ( ) Serious adverse event 321 (52.9) (45.5) (38.6) (35.6) 17.0 Rate ratio (95% CI) 0.78 ( ) 0.87 ( ) Death 40 (6.6) (5.6) (4.6) (3.1) 1.2 Rate ratio (95% CI) 0.82 ( ) 0.66 ( ) Adverse event leading to 167 (27.5) (22.9) (16.6) (15.4) 6.2 discontinuation Rate ratio (95% CI) 0.79 ( ) 0.90 ( ) Confirmed hypoglycemic 233 (38.4) (32.3) (24.2) (26.3) 12.8 adverse event* Rate ratio (95% CI) 0.78 ( ) 1.10 ( ) Requiring assistance 18 (3.0) (1.9) (1.0) (1.2) 0.4 Rate ratio (95% CI) 0.62 ( ) 1.06 ( ) Event consistent with urinary tract infection 132 (21.7) (22.9) (16.9) (16.2) 6.9 Rate ratio (95% CI) 1.06 ( ) 0.92 ( ) 21

23 Complicated urinary tract 17 (2.8) (3.1) (1.4) (1.3) 0.5 infection Rate ratio (95% CI) ( ) ( ) Event consistent with genital 10 (1.6) (5.3) (1.9) (6.8) 2.7 infection Rate ratio (95% CI) ( ) ( ) Event consistent with volume 49 (8.1) (6.7) (3.8) (4.5) 1.8 depletion Rate ratio (95% CI) ( ) ( ) Acute renal failure ǁ 87 (14.3) (11.2) (3.9) (3.2) 1.2 Rate ratio (95% CI) 0.75 ( ) Acute kidney injury 22 (3.6) (2.1) (0.9) (0.5) 0.2 Diabetic ketoacidosis** 1 (0.2) (0.2) (0.1) <0.1 Thromboembolic event 7 (1.2) (1.1) (0.8) (0.5) ( ) Rate ratio (95% CI) 0.89 ( ) 0.63 ( ) Bone fracture 32 (5.3) (4.7) (3.4) (3.5) 1.4 Rate ratio (95% CI) 0.86 ( ) 0.99 ( ) Hyperkalemia 42 (6.9) (3.9) (2.1) (1.3) 0.5 Rate ratio (95% CI) 0.53 ( ) 0.61 ( ) Data are from patients treated with 1 dose of study drug based on events that occurred during treatment or 7 days after the last intake of study drug. Post-hoc assessments. * Plasma glucose 70 mg/dl and/or requiring assistance. Based on 79 MedDRA preferred terms. Pyelonephritis, urosepsis or serious adverse event consistent with urinary tract infection. Based on 88 MedDRA preferred terms. Based on 8 MedDRA preferred terms. ǁ Based on the narrow standardized MedDRA query acute renal failure. ** Based on 4 MedDRA preferred terms. Incidence rate ratio and 95% confidence interval not calculated due to low number of events. Based on 1 standardized MedDRA query Based on 62 MedDRA preferred terms. Based on 2 MedDRA preferred terms. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. 22

24 Table S7. Complicated urinary tract infections by MedDRA preferred term in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline Patients with egfr (MDRD) <60 ml/min/1.73m 2 at baseline Patients with egfr (MDRD) 60 ml/min/1.73m 2 at baseline Placebo (N = 607) Empagliflozin (N = 1212) Placebo (N = 1726) Empagliflozin (N = 3473) no. (%) with one or more event Complicated urinary tract infection 17 (2.8) 37 (3.1) 24 (1.4) 45 (1.3) Urinary tract infection 7 (1.2) 15 (1.2) 9 (0.5) 14 (0.4) Urosepsis 2 (0.3) 9 (0.7) 1 (0.1) 8 (0.2) Pyelonephritis 2 (0.3) 4 (0.3) 2 (0.1) 9 (0.3) Pyelonephritis chronic 4 (0.7) 5 (0.4) 6 (0.3) 5 (0.1) Pyelonephritis acute 1 (0.2) 4 (0.3) 5 (0.3) 4 (0.1) Cystitis (0.1) 0 Kidney infection 2 (0.3) 1 (0.1) 0 3 (0.1) Urinary tract infection fungal 0 2 (0.2) 0 1 (<0.1) Cystitis bacterial (0.1) 0 Escherichia urinary tract infection 1 (0.2) Urinary tract infection (<0.1) pseudomonal Cystitis glandularis (<0.1) Cystitis hemorrhagic (0.1) 0 Nephritis (<0.1) Data are from patients treated with 1 dose of study drug based on events that occurred during treatment or 7 days after the last intake of study medication. Complicated urinary tract infection defined as pyelonephritis, urosepsis or serious adverse event consistent with urinary tract infection. MedDRA, Medical Dictionary for Regulatory Activities. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. 23

25 Table S8. Changes in clinical laboratory parameters in patients with egfr (MDRD) <60 and 60 ml/min/1.73m 2 at baseline. Patients with egfr (MDRD) <60 ml/min/1.73m 2 at baseline Patients with egfr (MDRD) 60 ml/min/1.73m 2 at baseline Placebo Empagliflozin Placebo Empagliflozin Baseline Change from baseline Baseline Change from baseline Baseline Change from baseline Baseline Change from baseline Hematocrit, % 40.3 ± ± ± ± ± ± ± ± 5.2 Hemoglobin, g/dl 13.1 ± ± ± ± ± ± ± ± 1.3 Aspartate 15 ± 12 0 ± ± 10-1 ± ± 12 1 ± ± 10 0 ± 23 aminotransferase, U/L Alanine aminotransferase, 17 ± 13-1 ± ± 10-1 ± ± 14 0 ± ± 12-2 ± 19 U/L Alkaline phosphatase, U/L 66 ± 35 8 ± ± 36 6 ± ± 31 4 ± ± 31 2 ± 26 Electrolytes Sodium, meq/l 141 ± 2 0 ± ± 2 0 ± ± 2 0 ± ± 2 0 ± 2 Potassium, meq/l 4.4 ± ± ± ± ± ± ± ± 0.4 Calcium, mg/dl 9.8 ± ± ± ± ± ± ± ± 0.5 Magnesium, meq/l 1.7 ± ± ± ± ± ± ± ± 0.2 Chloride, meq/l 102 ± 2-1 ± ± 2-1 ± ± 2-1 ± ± 2-1 ± 2 Phosphate, mg/dl 3.7 ± ± ± ± ± ± ± ± 0.3 Plus-minus values are means ± SD and data are normalized to a standard reference range. Changes from baseline are the last measurement 3 days after the last intake of study medication. Data are from patients treated with 1 dose of study drug with a baseline and on-treatment measurement. Conversion factors: sodium, potassium, chloride and phosphate: 1 meq/l = 1 mmol/l; calcium: 1 mg/dl = 0.25 mmol/l; magnesium: 1 meq/l = 0.5 mmol/l. egfr, estimated glomerular filtration rate. MDRD, Modification of Diet in Renal Disease. Hematocrit: Placebo n=587 and empagliflozin n=1141 for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1671 and empagliflozin n=3355 for patients with egfr 60 ml/min/1.73m 2 at baseline. Hemoglobin: Placebo n=589 and empagliflozin n=1145 for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1674 and empagliflozin n=3366 for patients with egfr 60 ml/min/1.73m 2 at baseline. 24

26 Aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase: Placebo n=603 and empagliflozin n=1182 for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1710 (or n=1709 for aspartate aminotransferase) and empagliflozin n=3430 for patients with egfr 60 ml/min/1.73m 2 at baseline. Electrolytes: Placebo n=588 and empagliflozin n=1150 (or n=1151 for potassium) for patients with egfr <60 ml/min/1.73m 2 at baseline; placebo n=1673 (or n=1672 for potassium) and empagliflozin n=3370 for patients with egfr 60 ml/min/1.73m 2 at baseline. 25

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes The new england journal of medicine Original Article and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, M.D., Silvio E. Inzucchi, M.D., John M. Lachin, Sc.D., David Fitchett, M.D.,

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

CANVAS Program Independent commentary

CANVAS Program Independent commentary CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

DIABETES AND CHRONIC KIDNEY DISEASE

DIABETES AND CHRONIC KIDNEY DISEASE DIABETES AND CHRONIC KIDNEY DISEASE Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

More information

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure. Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Patient enrolment details CKDOD registry

Patient enrolment details CKDOD registry Patient enrolment details CKDOD registry Personal Information Date of enrolment D D Date of birth D D Gender Descent Height cm m History of smoking Y N U Date of first diagnosis of CKD D D Primary Cause

More information

Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza

Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management Fabio Mazza CKD (Chronic Kidney Disease) is an ever-increasing clinical condition marked by a progressive reduction

More information

PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME 217 American Society of Nephrology Meeting Geoffrey A. Block 1, Pablo E. Pergola 2, Lesley

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr Current Management Strategies in Chronic Kidney Disease Grace Lin, MD Assistant Professor of Medicine, University of California San Francisco Case #1 50 y.o. 70 kg man with long-standing hypertension is

More information

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the

More information

No Increased Cardiovascular Risk for Lixisenatide in ELIXA

No Increased Cardiovascular Risk for Lixisenatide in ELIXA ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Understanding Blood Tests

Understanding Blood Tests PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away

More information

Diabetes Control and Complications in Public Hospitals in Malaysia

Diabetes Control and Complications in Public Hospitals in Malaysia ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,

More information

Primary Care Approach to Management of CKD

Primary Care Approach to Management of CKD Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE

CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence

More information

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing

More information

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes The new england journal of medicine Original Article, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D.,

More information

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD

More information

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. George L.

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. George L. REVIEW DIFFERENT STAGES OF NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George

More information

Clinical Practice Guidelines for Diabetes Management

Clinical Practice Guidelines for Diabetes Management Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can

More information

TREATMENT AND COMPLICAtions

TREATMENT AND COMPLICAtions ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Kidney Disease, Hypertension and Cardiovascular Risk

Kidney Disease, Hypertension and Cardiovascular Risk 1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,

More information

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2015.10.037

More information

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil

More information

Byvalson. (nebivolol, valsartan) New Product Slideshow

Byvalson. (nebivolol, valsartan) New Product Slideshow Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

KEEP 2.0 Annual Data Report Chapter Five

KEEP 2.0 Annual Data Report Chapter Five KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All

More information

E.Ritz Heidelberg (Germany)

E.Ritz Heidelberg (Germany) Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients

More information

ABFM Diabetes SAM Part 4

ABFM Diabetes SAM Part 4 ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular

More information

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN** Documentation and coding guide Disease definitions* HTN is diagnosed when the average of two or more (systolic of diastolic) blood pressure readings are found to be elevated on two or more office visits

More information

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College

More information

Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Executive Summary

Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Executive Summary Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Executive Summary Canadian Diabetes Association Clinical Practice Guidelines Expert

More information

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,

More information

Chronic Kidney Disease: Optimal and Coordinated Management

Chronic Kidney Disease: Optimal and Coordinated Management Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,

More information

Safety of Anacetrapib in Patients with or

Safety of Anacetrapib in Patients with or Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.

More information

KEEP 2009 Summary Figures

KEEP 2009 Summary Figures S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving

More information

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study DOI 10.1007/s13300-017-0337-5 ORIGINAL RESEARCH in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study George Grunberger. Sarah Camp. Jeremy Johnson.

More information

EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events

EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events EVOLVE EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events N Engl J Med online Nov 3, 2012 Glenn M. Chertow, Geoffrey A. Block, Ricardo Correa-Rotter, Tilman B. Drüeke, Jürgen Floege, William

More information

A Fork in the Road: Navigating Through New Terrain

A Fork in the Road: Navigating Through New Terrain A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes

More information

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes http://www.kidney-international.org & 2014 International Society of Nephrology Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes Vasilios

More information

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this

More information

DIABETES AND METABOLIC SYNDROME

DIABETES AND METABOLIC SYNDROME TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

*Sections or subsections omitted from the full prescribing information are not listed.

*Sections or subsections omitted from the full prescribing information are not listed. US-13287 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XIGDUO XR safely and effectively. See full prescribing information for XIGDUO XR. XIGDUO

More information

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2 Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic

More information

Chapter 2 Chronic Kidney Disease (CKD) in Cancer Patients

Chapter 2 Chronic Kidney Disease (CKD) in Cancer Patients Chapter 2 Chronic Kidney Disease (CKD) in Cancer Patients Mala Sachdeva, Amit Lahoti and Anna Mathew List of Abbreviations ACE Angiotensin converting enzyme AKI Acute kidney injury ARB Angiotensin II receptor

More information

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis

More information

ARE YOU AT INCREASED RISK FOR CHRONIC KIDNEY DISEASE?

ARE YOU AT INCREASED RISK FOR CHRONIC KIDNEY DISEASE? ARE YOU AT INCREASED RISK FOR CHRONIC KIDNEY DISEASE? www.kidney.org National Kidney Foundation s Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation s Kidney Disease

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

INVOKAMET XR (canagliflozin and metformin hydrochloride extended-release)

INVOKAMET XR (canagliflozin and metformin hydrochloride extended-release) INVOKAMET XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use Revised: 07/2017 076317-170714 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all

More information

Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care

Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome: Why Should We Look For It? 021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you

More information

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative

More information

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Chronic Benefit Application Form Cardiovascular Disease and Diabetes Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

PROs for Drug Development. Melanie Blank, MD

PROs for Drug Development. Melanie Blank, MD PROs for Drug Development in Chronic Kidney Disease Melanie Blank, MD Disclaimer The views expressed here represent my opinions and do not necessarily represent the views of the FDA. Overview Stagnation

More information

Microvascular Disease in Type 1 Diabetes

Microvascular Disease in Type 1 Diabetes Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course

More information

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus original article Effects of Blood-Pressure Control in Type 2 Diabetes Mellitus The ACCORD Study Group* ABSTRACT Background There is no evidence from randomized trials to support a strategy of lowering

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA

More information

Intervention Recommendations with Class of Recommendation and Level of Evidence

Intervention Recommendations with Class of Recommendation and Level of Evidence Intervention Recommendations with Class of Recommendation and Level of Evidence RISK: BLOOD PRESSURE CONTROL: LIPID Goal: to identify people who will benefit from risk reduction strategies Goal:

More information

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Authors: Pamela Piscitelli 1, Francesca Viazzi 2 ; Paola Fioretto

More information

Talking about blood pressure

Talking about blood pressure Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight

More information

Guidelines for Management of Chronic Conditions

Guidelines for Management of Chronic Conditions Guidelines for Management of Chronic Conditions 1. DIABETES: If you have high blood sugar or Diabetes, the following are recommended: Goals to prevent progression of diabetes and reducing complications

More information

Metabolic acidosis, including diabetic ketoacidosis (1, 4, 5.1) History of serious hypersensitivity reaction to empagliflozin or metformin (4)

Metabolic acidosis, including diabetic ketoacidosis (1, 4, 5.1) History of serious hypersensitivity reaction to empagliflozin or metformin (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNJARDY XR safely and effectively. See full prescribing information for SYNJARDY XR. SYNJARDY XR

More information

Empagliflozin (type 2 diabetes mellitus)

Empagliflozin (type 2 diabetes mellitus) IQWiG Reports Commission o. A16-46 Empagliflozin (type 2 diabetes mellitus) Addendum to Commission A16-12 1 Addendum Commission:A16-46 Version: 1.0 Status: 29 July 2016 1 Translation of addendum A16-46

More information